Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
Coverage of the 2012 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section
11/13/12
AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 12 November 2012 00:00
- Written by Keith Alcorn
Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb (BMS) to treat hepatitis C was highly effective in curing the infection in previous null responders with HCV genotype 1b infection, some new antiviral drugs may still need to be administered with interferon in harder-to-treat patients with genotype 1a, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.
Bacterial Translocation Linked to Severe Liver Disease among HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Friday, 02 November 2012 00:00
- Written by Liz Highleyman
HIV positive people with hepatitis C coinfection who had evidence of intestinal bacteria in their blood -- known as bacterial translocation -- had more advanced liver fibrosis and faster fibrosis progression, researchers reported in the August 28, 2012, advance edition of the Journal of Acquired Immune Deficiency Syndromes. 
AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.
Hepatitis C Raises Risk of Both Liver-Related and Non-Liver Deaths
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 24 July 2012 00:00
- Written by Liz Highleyman
Overall mortality from both liver-related disease and non-liver conditions -- including some cancers -- is significantly increased in people with chronic hepatitis C virus (HCV) infection compared with uninfected individuals, according to a study published in the July 17, 2012, advance online edition of the Journal of Infectious Diseases.
Web Design and Development by